Search
MORE TO EXPLORE
Expert Perspectives is the home to the voices of industry leaders, as they share their expertise and insights directly from the field.
The Broker Innovation Lab celebrates brokers and other benefits stakeholders who have embraced the changing marketplace to position themselves and their business for future success
Media & Resources
23andMe will pay $400 million for drug-delivery service Lemonaid in a bid to make its personalized genetics approach part of patients' primary care.
Verily hopes that its data-crunching and technological prowess can help employers more accurately assess what sort of risks they face.
GoodRx joins the ever-growing list of companies seeking to turn quick, convenient online doctor visits into big business.
In one instance, Medicaid recipients were offered $20 for DNA swabs and their health insurance information.
The Trump administration and Congress are gearing up for a renewed campaign to bring the companies to heel. Will it work?
The genotyping data a customer gets from 23andMe, for example, would be worth 50 shares, according to Luna.